Literature DB >> 29609501

The relationship between obesity and the severity of non-alcoholic fatty liver disease: systematic review and meta-analysis.

Feng-Bin Lu1, En-De Hu1, Lan-Man Xu1, Lu Chen1, Jin-Lu Wu1, Hui Li1, Da-Zhi Chen2, Yong-Ping Chen1.   

Abstract

INTRODUCTION: A number of researches have explored the association between obesity and nonalcoholic fatty liver disease (NAFLD) liver function, histopathology, complications, genetic factors and prognosis, but the results were conflicting and inconclusive. Areas covered: In this meta-analysis, the liver function, histopathology, metabolic complications, patatin-like phospholipase domain-containing protein 3 (PNPLA3) genetic polymorphism and prognosis were compared between non-obese and obese NAFLD. Pubmed, EMBASE, Cochrane databases were searched to identify eligible studies. The odds ratio (OR) or standardized mean difference (SMD) with 95% confidence intervals (CI) were pooled using fixed- or random-effects models. Expert commentary: This meta-analysis indicated that for NAFLD patients, obesity (according to ethnic-specific BMI cut-off points to define obesity) could predict a worse long-term prognosis. However, obesity may not be an independent factor for the development of NASH or advanced fibrosis in NAFLD patients and NAFLD should be considered as potential population for pharmacologic treatment regardless of obesity. In addition, PNPLA3 rs738409 may be more relevant to the progression of non-obese NAFLD when compared to obese NAFLD. Importantly, large-sample, long-term follow-up cohort studies based on liver biopsy are highly needed due to limited liver pathology and long-term follow-up data at present.

Entities:  

Keywords:  Liver disease; fatty liver; liver fibrosis; metabolic syndrome; obesity

Mesh:

Substances:

Year:  2018        PMID: 29609501     DOI: 10.1080/17474124.2018.1460202

Source DB:  PubMed          Journal:  Expert Rev Gastroenterol Hepatol        ISSN: 1747-4124            Impact factor:   3.869


  23 in total

Review 1.  Therapeutic implications of shared mechanisms in non-alcoholic fatty liver disease and chronic kidney disease.

Authors:  Mehmet Kanbay; Mustafa C Bulbul; Sidar Copur; Baris Afsar; Alan A Sag; Dimitrie Siriopol; Masanari Kuwabara; Silvia Badarau; Adrian Covic; Alberto Ortiz
Journal:  J Nephrol       Date:  2020-05-21       Impact factor: 3.902

2.  Non-Alcoholic Fatty Liver Disease in Long-Term Type 2 Diabetes: Role of rs738409 PNPLA3 and rs499765 FGF21 Polymorphisms and Serum Biomarkers.

Authors:  Mauy Frujuello Mana; Maria Cândida R Parisi; Maria Lucia Correa-Giannella; Arnaldo Moura Neto; Ademar Yamanaka; Marlone Cunha-Silva; Ana Mercedes Cavaleiro; Cristina Rodrigues Dos Santos; Célia Regina Pavan; Tiago Sevá-Pereira; Sergio S J Dertkigil; Daniel F Mazo
Journal:  Molecules       Date:  2022-05-17       Impact factor: 4.927

3.  Serum glycated albumin predicts all-cause mortality in dialysis patients with diabetes mellitus: meta-analysis and systematic review of a predictive biomarker.

Authors:  Sidar Copur; Dimitrie Siriopol; Baris Afsar; Melis C Comert; Gizem Uzunkopru; Alan A Sag; Alberto Ortiz; Adrian Covic; Daniel H van Raalte; David Z Cherney; Peter Rossing; Mehmet Kanbay
Journal:  Acta Diabetol       Date:  2020-08-30       Impact factor: 4.280

4.  Characterization of the variability in the extent of nonalcoholic fatty liver induced by a high-fat diet in the genetically diverse Collaborative Cross mouse model.

Authors:  Aline de Conti; Volodymyr Tryndyak; Rose A Willett; Barbara Borowa-Mazgaj; Anna Watson; Ralph Patton; Sangeeta Khare; Levan Muskhelishvili; Greg R Olson; Mark I Avigan; Carl E Cerniglia; Sharon A Ross; Arun J Sanyal; Frederick A Beland; Ivan Rusyn; Igor P Pogribny
Journal:  FASEB J       Date:  2020-04-18       Impact factor: 5.191

5.  Causal relationships between NAFLD, T2D and obesity have implications for disease subphenotyping.

Authors:  Zhipeng Liu; Yang Zhang; Sarah Graham; Xiaokun Wang; Defeng Cai; Menghao Huang; Roger Pique-Regi; Xiaocheng Charlie Dong; Y Eugene Chen; Cristen Willer; Wanqing Liu
Journal:  J Hepatol       Date:  2020-03-10       Impact factor: 25.083

Review 6.  Physiological Changes and Pathological Pain Associated with Sedentary Lifestyle-Induced Body Systems Fat Accumulation and Their Modulation by Physical Exercise.

Authors:  Enrique Verdú; Judit Homs; Pere Boadas-Vaello
Journal:  Int J Environ Res Public Health       Date:  2021-12-17       Impact factor: 3.390

7.  Therapeutic Effects of Resveratrol on Nonalcoholic Fatty Liver Disease Through Inflammatory, Oxidative Stress, Metabolic, and Epigenetic Modifications.

Authors:  Mina Karimi; Behnaz Abiri; Paul C Guest; Mohammadreza Vafa
Journal:  Methods Mol Biol       Date:  2022

8.  Evaluation of the Impact of Metabolic Syndrome on Fibrosis in Metabolic Dysfunction-Associated Fatty Liver Disease.

Authors:  Haluk Tarik Kani; Coskun Ozer Demirtas; Caglayan Keklikkiran; Ilkay Ergenc; Shahin Mehdiyev; Esra Akdeniz; Yusuf Yilmaz
Journal:  Turk J Gastroenterol       Date:  2021-08       Impact factor: 1.852

9.  Histologically proven hepatic steatosis associates with lower testosterone levels in men with obesity.

Authors:  Frederique Van de Velde; Marlies Bekaert; Anne Hoorens; Anja Geerts; Guy T'Sjoen; Tom Fiers; Jean-Marc Kaufman; Yves Van Nieuwenhove; Bruno Lapauw
Journal:  Asian J Androl       Date:  2020 May-Jun       Impact factor: 3.285

10.  Effect of Deglycosylated Rutin by Acid Hydrolysis on Obesity and Hyperlipidemia in High-Fat Diet-Induced Obese Mice.

Authors:  Jinwoo Yang; Junsoo Lee; Younghwa Kim
Journal:  Nutrients       Date:  2020-05-25       Impact factor: 5.717

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.